CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...